8-KExhibits & Filings

ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Exhibit Filing (Oct 2, 2015)

Filed October 2, 2015For Securities:ALNY

Summary

Alnylam Pharmaceuticals, Inc. (ALNY) filed this Form 8-K on October 2, 2015, primarily to provide unredacted versions of two key agreements: a Confidential Settlement Agreement and Mutual Release dated March 14, 2011, and an Exclusive License Agreement for Tuschl II United States Patents and Patent Applications dated March 14, 2011. These documents were originally filed with a Quarterly Report on Form 10-Q in May 2011, but contained redacted information for which the confidential treatment period has now expired. For investors, the significance of this filing lies in the transparency it offers regarding Alnylam's foundational intellectual property and prior legal arrangements. The unredacted agreements relate to crucial patents and applications, likely underpinning Alnylam's RNA interference (RNAi) therapeutics. Investors can now gain a clearer understanding of the terms, conditions, and parties involved in securing rights to these key technologies, which is fundamental to the company's long-term strategy and potential.

Key Highlights

  • 1Alnylam Pharmaceuticals is filing an 8-K to unredact previously confidential sections of two material agreements.
  • 2The unredacted documents include a Confidential Settlement Agreement and Mutual Release dated March 14, 2011.
  • 3The second unredacted document is an Exclusive License Agreement for Tuschl II United States Patents and Patent Applications, also dated March 14, 2011.
  • 4These agreements were originally filed with a Form 10-Q on May 5, 2011, but had confidential treatment applied to certain information.
  • 5The confidential treatment period for the redacted information in these exhibits has expired, necessitating this filing.
  • 6The settlement and license agreements are likely critical to Alnylam's intellectual property portfolio and its RNAi therapeutic development programs.
  • 7This filing provides increased transparency for investors into the foundational agreements governing Alnylam's core technologies.

Frequently Asked Questions

The primary purpose of this 8-K filing is to make publicly available the unredacted versions of two agreements that were previously filed with confidential information redacted. The confidential treatment period for these sections has expired.

The filing unredacts a Confidential Settlement Agreement and Mutual Release, and an Exclusive License Agreement for Tuschl II United States Patents and Patent Applications. Both agreements are dated March 14, 2011.

These documents were originally filed with redactions under confidential treatment. This is common practice for material agreements where certain terms are considered commercially sensitive or proprietary, and the company seeks to protect this information for a defined period.

While this specific 8-K doesn't detail the patents, the Tuschl II patents are widely recognized as foundational intellectual property related to RNA interference (RNAi) technology. Alnylam's business model is centered on developing RNAi therapeutics, making these licenses and associated patents crucial to their platform and drug pipeline.